Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy
Molecular Pharmaceutics · 01.09.2025 · 22 (9) · 5603-5615
DOI: 10.1021/acs.molpharmaceut.5c00646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 13.08.2025. Verfasst von De-Chao Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Technology, Putian University, Putian 351100, China. Hauptthemen laut MEDLINE: Boron Compounds, Photochemotherapy, Photosensitizing Agents, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, The Open Project Program of Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine (Putian University), Young and Middle-aged Teachers' Educational Research Project of Fujian Province.
Abstract (Originalsprache)
The integration of chemotherapeutic drugs and photosensitizers into nanocarriers holds great potential for combining chemotherapy and phototherapy while reducing systemic toxicity. However, therapeutic efficacy is hindered by the hypoxic tumor microenvironment and the insufficient drug release. This study designs a multifunctional nano-photosensitizer BAP by conjugating hydrophobic boron dipyrromethene (BODIPY) with hydrophilic poly(ethylene glycol) via hypoxia-responsive azobenzene linkers. In aqueous media, BAP demonstrates self-assembly into stable nanoparticles (termed BAP NPs) that exhibit dual phototherapeutic functionalities. BAP NPs can be activated by single wavelength laser irradiation to initiate both photodynamic therapy (PDT) and photothermal therapy (PTT). The engineered BAP NPs further integrate dual-mode imaging capabilities, enabling fluorescence and photothermal imaging for nanocarrier visualization. To enhance antitumor efficacy, the chemotherapy doxorubicin (DOX) was further loaded into BAP NPs, forming nanomedicine BAP-DOX NPs. As expected, the azobenzene linkers of BAP are sensitive to the overexpressed azoreductase in hypoxic cancer cells, facilitating BAP disassembly and DOX release. Upon laser irradiation, the BAP component in BAP-DOX NPs eradicates superficial oxygen-rich tumor cells through PDT and PTT. PDT-caused oxygen consumption triggers acute hypoxia, enhancing DOX release in hypoxic tumor cells. Both in vitro and in vivo studies have demonstrated that BAP-DOX NPs exhibit remarkable antitumor activity through synergistic light-driven PDT/PTT and hypoxia-responsive chemotherapy. This research establishes an innovative therapeutic strategy to overcome hypoxia-induced therapeutic resistance through a simple photosensitizer-based nanocarrier that enables photo-enhanced drug release and synergistic chemo/photodynamic/photothermal tumor ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Medical Technology, Putian University, Putian 351100, China.
- Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine (Putian University), Fujian Province University, Putian 351100, China.
- Key Laboratory of Medical Microecology (Putian University), Fujian Province University, Putian 351100, China.
- National & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
ORCID-Profile: De-Chao Yang, Liyang Du, Jianmin Chen, Jian-Yong Liu
Förderung
- Natural Science Foundation of Fujian Province
- The Open Project Program of Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine (Putian University)
- Young and Middle-aged Teachers' Educational Research Project of Fujian Province
- Startup Fund for Advanced Talents of Putian University
Zitieren
APA
Yang, D. C., Zhuang, H., Zheng, J., Du, L., Chen, J., & Liu, J. Y. (2025). Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy. Molecular Pharmaceutics, 22(9), 5603-5615. https://doi.org/10.1021/acs.molpharmaceut.5c00646
Vancouver
Yang DC, Zhuang H, Zheng J, Du L, Chen J, Liu JY. Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy. Molecular Pharmaceutics. 2025;22(9):5603-5615. doi:10.1021/acs.molpharmaceut.5c00646
BibTeX
@article{Yang2025,
author = {Yang, De-Chao and Zhuang, Huamei and Zheng, Jiayi and Du, Liyang and Chen, Jianmin and Liu, Jian-Yong},
title = {Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {9},
pages = {5603--5615},
doi = {10.1021/acs.molpharmaceut.5c00646}
}
EUVIMED